IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
Bologna, Italy4 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) | Bladder Carcinoma in Situ (CIS) | Active, not recruiting | Phase 3 | 2026-06-23 | NCT05024773 | |
| (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, gastrointestinal stromal tumor, metastatic malignant neoplasm, neoplasm | Recruiting | Phase 3 | 2026-06-16 | NCT05208047 | |
| (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | Hemic and Lymphatic Diseases, Mast Cell Activation Disorders, Mastocytosis, Systemic, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, hematologic disorder, immune system disorder, indolent systemic mastocytosis, mastocytosis, neoplasm, superficial spreading melanoma, type III hypersensitivity disease | Active, not recruiting | Phase 2 | 2026-05-22 | NCT05186753 | |
| Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Recruiting | Phase 1 / Phase 2 | 2023-02-21 | NCT05280509 |